There has been much talk recently about the possible benefits of medicines derived from cannabis plants. With public pressure on governments to relax legislation, and increasing enthusiasm for investors, how positive is the prospect for these products?
In a series of two articles, Medilink EM Patron Mills and Reeve consider some of the recent changes to policy and approach, and obstacles that stand in the way for developers.
